Abstract | BACKGROUND:
Neuromuscular blocking agents' detrimental airway effects may occur as a result of interactions with muscarinic receptors, allergic reactions, or histamine release. Rapacuronium, a nondepolarizing muscle relaxant, was withdrawn from clinical use because of its association with fatal bronchospasm. Despite its withdrawal from clinical use, it is imperative that the mechanism by which bronchospasm occurred is understood so that new muscle relaxants introduced to clinical practice do not share these same detrimental airway effects. METHODS: RESULTS: CONCLUSION:
|
Authors | Edmund H Jooste, Amit Sharma, Yi Zhang, Charles W Emala |
Journal | Anesthesiology
(Anesthesiology)
Vol. 103
Issue 6
Pg. 1195-203
(Dec 2005)
ISSN: 0003-3022 [Print] United States |
PMID | 16306732
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Inositol Phosphates
- Neuromuscular Nondepolarizing Agents
- Parasympatholytics
- Receptor, Muscarinic M3
- Vecuronium Bromide
- rapacuronium
- Acetylcholine
- N-Methylscopolamine
|
Topics |
- Acetylcholine
(pharmacology)
- Animals
- Bronchoconstriction
(drug effects)
- Drug Synergism
- Guinea Pigs
- In Vitro Techniques
- Inositol Phosphates
(metabolism)
- Kinetics
- Muscle Contraction
(drug effects)
- Muscle, Smooth
(drug effects)
- N-Methylscopolamine
(pharmacology)
- Neuromuscular Nondepolarizing Agents
(pharmacology)
- Parasympatholytics
(pharmacology)
- Radioligand Assay
- Receptor, Muscarinic M3
(drug effects)
- Stereoisomerism
- Trachea
(drug effects)
- Vecuronium Bromide
(analogs & derivatives, pharmacology)
|